KR940013542A - 마그네타이트-덱스트란 미소립자의 자기적 성질 및 제조방법 - Google Patents

마그네타이트-덱스트란 미소립자의 자기적 성질 및 제조방법 Download PDF

Info

Publication number
KR940013542A
KR940013542A KR1019930022699A KR930022699A KR940013542A KR 940013542 A KR940013542 A KR 940013542A KR 1019930022699 A KR1019930022699 A KR 1019930022699A KR 930022699 A KR930022699 A KR 930022699A KR 940013542 A KR940013542 A KR 940013542A
Authority
KR
South Korea
Prior art keywords
particles
dispersant
sensitive material
magnetic sensitive
mixture
Prior art date
Application number
KR1019930022699A
Other languages
English (en)
Inventor
에스. 유델슨 죠셉
Original Assignee
폴 이. 듀퐁
스터얼링 윈드롭 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 이. 듀퐁, 스터얼링 윈드롭 아이엔씨. filed Critical 폴 이. 듀퐁
Publication of KR940013542A publication Critical patent/KR940013542A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Power Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Iron (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Hard Magnetic Materials (AREA)

Abstract

본원은 자기적 감응물질 및 분산제로 구성되고 최소한 90%의 입도가 약 2 내지 약 10nm인 입자들에 관한다. 본원은 또한 자기적 감응물질을 분산제와 혼합하여 혼합물을 만들고 자기적 감응물질-분산제 입자를 형성하기에 적당한 조건하에서 일정시간동안 이 혼합물을 염기와 접촉시키는 것으로 구성되는 상기 입자들 을 제조하는 방법에 관한다. 바람직한 구체예에서, 자기적 감응물질은 마그네타이트이고 분산제는 덱스트란, 염기는 암모늄 하이드록사이드이다. 또다른 바람직한 구체예에서는, 상기 혼합물은 겔상에 현탁된다. 본원은 또 생리적으로 용인할만한 담체내에 현탁 또는 분산시킨 상기 입자들을 조영유효량 포유동물에 투여하여 그 포유동물의 NMR 이미지를 얻는 것으로 구성되는 진단 방법에 관한다.

Description

마그네타이트-덱스트란 미소립자의 자기적 성질 및 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 자기적 감응물질 및 분산제로 구성되고 최소한 90%의 입도가 약 2 내지 약 10nm인 입자들.
  2. 제 1 항에 있어서, 자기적 감응물질이 마그네타이트인 입자들.
  3. 제 1 항에 있어서, 분산제가 덱스트란인 입자들.
  4. 제 1 항에 있어서, 최소한 90%의 입도가 약 2 내지 약 5nm인 입자들.
  5. 자기적 감응물질을 분산제와 혼합하여 혼합물을 만들고 자기적 감응물질-분산제 입자를 형성하기에 적당한 조건하에 일정시간동안 이 혼합물을 염기와 접촉시키는 것으로 구성되는 제 1 항의 입자들을 제조하는 방법.
  6. 제 5 항에 있어서, 자기적 감응물질이 마그네타이트인 방법.
  7. 제 5 항에 있어서, 분산제가 덱스트란인 방법.
  8. 제 5 항에 있어서, 입자들의 입도 범위가 막 2 내지 약 10nm인 방법.
  9. 제 5 항에 있어서, 첫번째 혼합물을 겔상에 현탁시키는 방법.
  10. 제 9 항에 있어서, 겔상이 젤라틴으로 형성된 방법.
  11. 제 9 항에 있어서, 겔상이 폴리비닐 알콜로 형성된 방법.
  12. 생리적으로 용인할만한 담체내에 현탁 또는 분산시킨 제 1항의 입자들을 조영유효량 포유동물에 투여하여 그 포유동물의 NMR 이미지를 얻는 것으로 구성되는 진단 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930022699A 1992-12-02 1993-10-29 마그네타이트-덱스트란 미소립자의 자기적 성질 및 제조방법 KR940013542A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92/984,611 1992-12-02
US07/984,611 US5349957A (en) 1992-12-02 1992-12-02 Preparation and magnetic properties of very small magnetite-dextran particles

Publications (1)

Publication Number Publication Date
KR940013542A true KR940013542A (ko) 1994-07-15

Family

ID=25530702

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930022699A KR940013542A (ko) 1992-12-02 1993-10-29 마그네타이트-덱스트란 미소립자의 자기적 성질 및 제조방법

Country Status (14)

Country Link
US (1) US5349957A (ko)
EP (1) EP0600529A3 (ko)
JP (1) JPH06218271A (ko)
KR (1) KR940013542A (ko)
AU (1) AU4747193A (ko)
CA (1) CA2107280A1 (ko)
CZ (1) CZ260193A3 (ko)
FI (1) FI935302A (ko)
HU (1) HUT69399A (ko)
IL (1) IL107617A0 (ko)
MX (1) MX9306009A (ko)
NO (1) NO934270L (ko)
NZ (1) NZ248701A (ko)
SK (1) SK135093A3 (ko)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021240A2 (de) * 1993-03-17 1994-09-29 Silica Gel Ges.M.B.H Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
EP0713602B1 (en) * 1993-08-12 2002-07-17 Advanced Magnetics Incorporated Use of polysaccharide covered superparamagnetic oxide colloids
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
ATE274341T1 (de) * 1995-02-24 2004-09-15 Elan Pharma Int Ltd Nanopartikel-dispersionen enthaltende aerosole
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
ATE291439T1 (de) 1996-01-10 2005-04-15 Amersham Health As Kontrastmittel
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
WO1999062079A1 (en) * 1998-05-26 1999-12-02 Bar-Ilan University Nucleation and growth of magnetic metal oxide nanoparticles and its use
US6315709B1 (en) * 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
DE69939748D1 (de) 1998-11-02 2008-11-27 Elan Pharma Int Ltd Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
DE19921088C2 (de) * 1999-04-30 2003-08-07 Magforce Applic Gmbh Stent zur Offenhaltung gangartiger Strukturen
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2451161A1 (en) * 2001-06-22 2003-01-03 Elan Pharma International, Ltd. Method for high through put screening using a small scale mill or microfluidics
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
PT1443912E (pt) 2001-10-12 2007-11-28 Elan Pharma Int Ltd Composições tendo uma combinação de características de libertação imediata e de libertação controlada
EP1450863A4 (en) * 2001-11-07 2009-01-07 Imcor Pharmaceutical Company PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
CA2479735C (en) * 2002-03-20 2011-05-17 Elan Pharma International Ltd. Fast dissolving dosage forms having reduced friability
WO2003081612A1 (en) * 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research Process for the preparation of nanosozed iron oxide by biomimetic route
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
WO2003082213A2 (en) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US6800271B2 (en) * 2002-04-01 2004-10-05 Council Of Scientific And Industrial Research Process for the preparation of nanosized iron oxide by biomimetic route
WO2003086354A1 (en) 2002-04-12 2003-10-23 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
JP2005529911A (ja) * 2002-05-06 2005-10-06 エラン ファーマ インターナショナル，リミティド ナノ粒子ナイスタチン製剤
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CA2488498A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US7842377B2 (en) 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
CA2498207C (en) * 2002-09-11 2012-03-13 Elan Pharma International Ltd. Gel-stabilized nanoparticulate active agent compositions
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US20040156895A1 (en) * 2002-11-12 2004-08-12 Elan Pharma International Ltd. Solid dosage forms comprising pullulan
WO2004058216A2 (en) * 2002-12-17 2004-07-15 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
EP1651189B1 (en) * 2003-08-08 2008-12-03 Elan Pharma International Limited Novel metaxalone compositions
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
JP4787165B2 (ja) * 2003-11-05 2011-10-05 エラン ファーマ インターナショナル，リミティド 表面安定剤としてペプチドを有するナノ粒子組成物
FR2861994A1 (fr) * 2003-11-12 2005-05-13 Guerbet Sa Nouvel agent de diagnostic pour l'irm dans les pathologies impliquant des proteinases
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US8425550B2 (en) 2004-12-01 2013-04-23 Boston Scientific Scimed, Inc. Embolic coils
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
KR20070116581A (ko) * 2004-12-15 2007-12-10 엘란 파마 인터내셔널 리미티드 나노입자형 타크롤리무스 제제
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
KR100637275B1 (ko) 2005-01-28 2006-10-23 한국지질자원연구원 초음파를 이용하여 제조된 ｍｒｉ 조영제에 사용되는산화철 나노분말 및 그 제조방법과 이를 이용한 ｍｒｉ조영제의 제조방법과 그 ｍｒｉ 조영제
EP2353590A1 (en) 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
JP2008533174A (ja) * 2005-03-16 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ロイコトリエン受容体拮抗薬／副腎皮質ステロイド製剤
EA200701997A1 (ru) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиция из наночастиц бисфосфоната
JP2008534509A (ja) * 2005-03-23 2008-08-28 エラン ファーマ インターナショナル リミテッド ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
BRPI0609071A2 (pt) * 2005-04-12 2010-11-16 Elan Pharma Int Ltd composicão estável de ciclosporina nanoparticulada, método para preparar uma ciclosporina nanoparticulada, uso da composição de ciclosporina nanoparticulada estável, e, composição de liberação controlada
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
EA015102B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Препараты наночастиц мезилата иматиниба
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
JP2009517485A (ja) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
DE602006010070D1 (de) * 2005-06-09 2009-12-10 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
EA200800041A1 (ru) * 2005-06-13 2008-04-28 Элан Фарма Интернэшнл Лтд. Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8007509B2 (en) 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
US8152839B2 (en) 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
EP2077731B1 (en) * 2006-01-17 2011-08-31 Philip Morris Products S.A. Cigarette components having encapsulated catalyst particles and methods of making and use thereof
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
MX2008015275A (es) * 2006-05-30 2009-02-06 Elan Pharma Int Ltd Formulaciones de posaconazol en nanoparticulas.
JP2009543797A (ja) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド ナノ粒子ソラフェニブ製剤
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP2011520779A (ja) * 2008-03-21 2011-07-21 エラン・ファルマ・インターナショナル・リミテッド イマチニブの部位特異的送達のための組成物および使用の方法
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
JP6072539B2 (ja) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
EP3288957A4 (en) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219554A (en) * 1986-07-03 1993-06-15 Advanced Magnetics, Inc. Hydrated biodegradable superparamagnetic metal oxides
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体

Also Published As

Publication number Publication date
EP0600529A2 (en) 1994-06-08
IL107617A0 (en) 1994-02-27
NO934270D0 (no) 1993-11-25
CA2107280A1 (en) 1994-06-03
CZ260193A3 (en) 1994-08-17
FI935302A0 (fi) 1993-11-29
HU9303415D0 (en) 1994-03-28
EP0600529A3 (en) 1995-10-25
HUT69399A (en) 1995-09-28
US5349957A (en) 1994-09-27
MX9306009A (es) 1995-01-31
SK135093A3 (en) 1994-09-07
NO934270L (no) 1994-06-03
NZ248701A (en) 1995-09-26
AU4747193A (en) 1994-06-16
FI935302A (fi) 1994-06-03
JPH06218271A (ja) 1994-08-09

Similar Documents

Publication Publication Date Title
KR940013542A (ko) 마그네타이트-덱스트란 미소립자의 자기적 성질 및 제조방법
BRENTARI Theoretical foundations of American sign language phonology
DE3689618D1 (de) Magnetische polymerteilchen.
KR940013516A (ko) 틸록사폴(Tyloxapol)을 미소입자 안정제 및 분산제로 사용하는 방법
ES2052224T3 (es) Microesferas "core-shell" magnetizables a base de organopolisiloxano reticulado, su procedimiento de preparacion y su aplicacion en biologia.
ATE281886T1 (de) Yttria partikelförmiges gut
DE59406230D1 (de) Präparat zur durchblutungsförderung das hartmagnetische teilchen enthält
DE68916048D1 (de) Verfahren zur Herstellung von monodispersen Polymerteilchen mit erhöhter Teilchengrösse.
ATE88277T1 (de) Gegen eine substanz mit niedrigem molekulargewicht spezifischer antikoerper und verfahren zu seiner herstellung mittels kolloidaler metallteilchen als traeger.
DE69001609D1 (de) Herstellung von niedrigviskosen fotografischen kleinteilchen-dispersionen in gelatine.
Biberfeld et al. Cytological observations on the cytotoxic interaction between lymphocytes and antibody-coated monolayer cells
KR930701972A (ko) 동결 건조 제제 및 이의 제조방법
DE69106002D1 (de) Testverfahren und reagenziensatz dafür.
GB1390872A (en) Carrier vehicle
JPS5466134A (en) Magnetic brush development method
ES345586A1 (es) Procedimiento de fabricacion de un reactivo para test sero-logico para el diagnostico de la sifilis.
ES2053153T3 (es) Microesferas magnetizables a base de polisilsesquioxano, su procedimiento de preparacion y su aplicacion en biologia.
Chase An evaluation of MMPI interpretation systems.
IT8422362A0 (it) Metodo per preparare una sospensione acquosa di particelledi combustibile carbonioso solido e sospensione acquosa cosi'preparata.
RU93054003A (ru) Многочувствительные частицы, способ их получения, способ диагностики
KR910005860A (ko) 항간질환성 조성물
Goss UTE LEXICAL AND PHONOLOGICAL PATTERNS.
Eckebil EVALUATION OF SORGHUM RANDOM-MATING POPULATIONS THROUGH S1-PROGENY TESTING.
NO922304L (no) Eliminering av aktiverte lymfocytter
Avanesov et al. Effect of Internal Stresses on Magnetomechanical Damping of Ferromagnetic Solids

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid